BR112019005725A2 - ajuste de dose - Google Patents
ajuste de doseInfo
- Publication number
- BR112019005725A2 BR112019005725A2 BR112019005725A BR112019005725A BR112019005725A2 BR 112019005725 A2 BR112019005725 A2 BR 112019005725A2 BR 112019005725 A BR112019005725 A BR 112019005725A BR 112019005725 A BR112019005725 A BR 112019005725A BR 112019005725 A2 BR112019005725 A2 BR 112019005725A2
- Authority
- BR
- Brazil
- Prior art keywords
- dose adjustment
- dose
- adjustment
- pibrentasvir
- glecaprevir
- Prior art date
Links
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- MLSQGNCUYAMAHD-ITNVBOSISA-N glecaprevir Chemical compound O=C([C@@H]1C[C@H]2OC3=NC4=CC=CC=C4N=C3C(F)(F)/C=C/CO[C@@H]3CCC[C@H]3OC(=O)N[C@H](C(N1C2)=O)C(C)(C)C)N[C@]1(C(=O)NS(=O)(=O)C2(C)CC2)C[C@H]1C(F)F MLSQGNCUYAMAHD-ITNVBOSISA-N 0.000 abstract 1
- 229950008970 glecaprevir Drugs 0.000 abstract 1
- VJYSBPDEJWLKKJ-NLIMODCCSA-N methyl n-[(2s,3r)-1-[(2s)-2-[6-[(2r,5r)-1-[3,5-difluoro-4-[4-(4-fluorophenyl)piperidin-1-yl]phenyl]-5-[6-fluoro-2-[(2s)-1-[(2s,3r)-3-methoxy-2-(methoxycarbonylamino)butanoyl]pyrrolidin-2-yl]-3h-benzimidazol-5-yl]pyrrolidin-2-yl]-5-fluoro-1h-benzimidazol-2 Chemical compound COC(=O)N[C@@H]([C@@H](C)OC)C(=O)N1CCC[C@H]1C1=NC2=CC(F)=C([C@@H]3N([C@H](CC3)C=3C(=CC=4N=C(NC=4C=3)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)[C@@H](C)OC)F)C=3C=C(F)C(N4CCC(CC4)C=4C=CC(F)=CC=4)=C(F)C=3)C=C2N1 VJYSBPDEJWLKKJ-NLIMODCCSA-N 0.000 abstract 1
- 229950007513 pibrentasvir Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Emergency Medicine (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
trata-se do ajuste de dose para fármacos coadministrados com glecaprevir e pibrentasvir.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662398724P | 2016-09-23 | 2016-09-23 | |
| US201762510936P | 2017-05-25 | 2017-05-25 | |
| PCT/US2017/052994 WO2018057919A1 (en) | 2016-09-23 | 2017-09-22 | Dose adjustment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112019005725A2 true BR112019005725A2 (pt) | 2019-07-09 |
Family
ID=61687385
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112019005725A BR112019005725A2 (pt) | 2016-09-23 | 2017-09-22 | ajuste de dose |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20180085330A1 (pt) |
| EP (1) | EP3515442A4 (pt) |
| JP (2) | JP2019529426A (pt) |
| CN (1) | CN109715161A (pt) |
| AU (2) | AU2017332771A1 (pt) |
| BR (1) | BR112019005725A2 (pt) |
| CA (1) | CA3037719A1 (pt) |
| MA (1) | MA46292A (pt) |
| MX (1) | MX2019003366A (pt) |
| WO (1) | WO2018057919A1 (pt) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008124384A2 (en) * | 2007-04-03 | 2008-10-16 | Aegerion Pharmaceuticals, Inc. | Combinations of mtp inhibitors with cholesterol absorption inhibitors or interferon for treating hepatitis c |
| WO2011009961A1 (en) * | 2009-07-24 | 2011-01-27 | Virologik Gmbh | Combination of proteasome inhibitors and anti-hepatitis medication for treating hepatitis |
| KR20140048229A (ko) * | 2009-09-14 | 2014-04-23 | 애브비 인코포레이티드 | 건선을 치료하는 방법 |
| SG11201401791WA (en) * | 2011-10-24 | 2014-08-28 | Abbvie Inc | Immunobinders directed against sclerostin |
| LT2968301T (lt) * | 2013-03-14 | 2017-05-25 | Abbvie Inc. | Dviejų antivirusinių vaistų derinys, skirtas hepatito c gydymui |
| MX2016012799A (es) * | 2014-04-02 | 2016-12-12 | Abbvie Inc | Metodos para tratar el virus de la hepatitis c. |
| EP3271371A4 (en) * | 2015-03-02 | 2018-12-05 | Medivir Aktiebolag | Nucleotide derivatives which are hcv inhibitors for use in the treatment of hepatitis c |
| MD20170081A2 (ro) * | 2015-03-04 | 2018-03-31 | Gilead Sciences, Inc. | Compuşi 4,6-diamino-pirido[3,2-D]pirimidină modulatori ai receptorilor de tip Toll |
-
2017
- 2017-09-22 CN CN201780058173.0A patent/CN109715161A/zh active Pending
- 2017-09-22 AU AU2017332771A patent/AU2017332771A1/en not_active Abandoned
- 2017-09-22 US US15/713,137 patent/US20180085330A1/en not_active Abandoned
- 2017-09-22 MX MX2019003366A patent/MX2019003366A/es unknown
- 2017-09-22 CA CA3037719A patent/CA3037719A1/en active Pending
- 2017-09-22 BR BR112019005725A patent/BR112019005725A2/pt unknown
- 2017-09-22 WO PCT/US2017/052994 patent/WO2018057919A1/en unknown
- 2017-09-22 MA MA046292A patent/MA46292A/fr unknown
- 2017-09-22 JP JP2019515224A patent/JP2019529426A/ja active Pending
- 2017-09-22 EP EP17854006.8A patent/EP3515442A4/en not_active Withdrawn
-
2022
- 2022-05-02 AU AU2022202895A patent/AU2022202895A1/en active Pending
- 2022-08-05 JP JP2022125281A patent/JP2022153655A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3037719A1 (en) | 2018-03-29 |
| JP2022153655A (ja) | 2022-10-12 |
| CN109715161A (zh) | 2019-05-03 |
| AU2022202895A1 (en) | 2022-05-26 |
| JP2019529426A (ja) | 2019-10-17 |
| EP3515442A1 (en) | 2019-07-31 |
| AU2017332771A1 (en) | 2019-04-04 |
| MA46292A (fr) | 2019-07-31 |
| WO2018057919A1 (en) | 2018-03-29 |
| US20180085330A1 (en) | 2018-03-29 |
| EP3515442A4 (en) | 2020-05-06 |
| MX2019003366A (es) | 2019-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2018002012A1 (es) | Derivados de maitansinoide, conjugados de los mismos y métodos de uso. | |
| ECSDI18019182S (es) | Dispositivo intranasal para suministro de fármacos | |
| CL2018003123A1 (es) | Terapia de combinación para el tratamiento del cáncer | |
| MD3209310T2 (ro) | Compoziții care conțin tulpini bacteriene | |
| CU20160185A7 (es) | Compuestos de heteroarilo para la inhibición de cinasa | |
| CL2017002422A1 (es) | Derivados de maitansinoide, conjugados de los mismos, y métodos de uso. | |
| MD3209381T2 (ro) | Compoziții care conțin tulpini bacteriene | |
| DOP2017000078A (es) | Indazoles sustituidos con bencilo como inhibidores de bub1. | |
| GEP20217239B (en) | Pharmaceutical composition | |
| ECSP17018120A (es) | Triazolopirazinonas como inhibidores de pde1 | |
| BR112018011133A2 (pt) | alvos terapêuticos para a correção do gene humano de distrofina por edição de gene e métodos de uso | |
| BR112017000130A2 (pt) | método para atenuar a toxicidade associada à inibição da via de notch e método de tratamento do câncer | |
| TWD174683S (zh) | 戒指 | |
| ECSP17015977A (es) | Terapia de combinacion | |
| MY195009A (en) | Cellular Targeted Active Ingredient Delivery System | |
| DOP2017000254A (es) | Imidazopirazinonas como inhibidores de pde1 | |
| EA201791454A1 (ru) | Лекарственные формы для трансдермального введения | |
| BR112018008103A2 (pt) | análogos de celastrol | |
| CU24407B1 (es) | Moduladores de pirrolopiridina de rorc2 sustituidos con metilo y trifluorometilo | |
| CL2015002180A1 (es) | Terapia de combinación para el tratamiento de neumonía nosocomial | |
| GEP20217240B (en) | Pharmaceutical composition | |
| BR112018070497A2 (pt) | métodos e formulações farmacêuticas para tratamento de condições oculares | |
| CL2016003074A1 (es) | Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer. | |
| CL2016002151A1 (es) | Derivados de piridazina para uso en la prevención o el tratamiento de un trastorno atáxico | |
| PH12017500602A1 (en) | Methods for treating ocular conditions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |